Sionna Therapeutics
Update in progressSION (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis (CF). Its portfolio includes galicaftor (SION-2222), a TMD1-directed CFTR modulator with Phase 2 data; navocaftor (SION-3067), a CFTR potentiator with Phase 2 data; SION-109 and SION-2851, CFTR correctors (Phase 1); and SION-451 and SION-719, NBD1 stabilizers (Phase 1 and Phase 2a, respectively). Formerly Sling Therapeutics, renamed in July 2021. Incorporated in 2019, based in Waltham, MA.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.20
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Michael Cloonan M.B.A.
- Founded2019
- Employees59
- Websitewww.sionnatx.com
Identifiers
- ISINUS8294011080
- FIGIBBG016X2DC85